GLP-1 & Incretin Science

What Is Liraglutide? The Bridge Generation

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Liraglutide is a GLP-1 analogue with roughly 97% homology to the native hormone, modified with a C16 palmitic acid chain that binds albumin and extends its half-life to around 13 hours, enough for daily dosing. It is the generation between exenatide and semaglutide.

Key facts

Class
GLP-1 receptor agonist (peptide analogue)
Developer
Novo Nordisk
Molecular weight
~3,751 Da
Molecular formula
C172H265N43O51
PubChem CID
16134956
Homology to native GLP-1
~97%
Lipid chain
C16 palmitic acid
Dosing
Once daily

The design step it represents

Exenatide showed that a protease-resistant GLP-1 receptor agonist worked. Liraglutide asked a different question: could the human hormone itself be modified rather than replaced by a lizard peptide? At roughly 97% homology to native GLP-1, it stays much closer to the original sequence than exenatide's 53%, and solves clearance by attaching a fatty acid rather than by substituting the whole molecule.

What the C16 chain does

Palmitic acid attached to the peptide binds reversibly to serum albumin. The bound complex is too large for glomerular filtration and is physically shielded from proteases, while a small free fraction remains available to engage the receptor. The result is a half-life of roughly 13 hours. A very large improvement on one to two minutes, and enough for once-daily dosing.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Why semaglutide went weekly and liraglutide did not

Chain length. Liraglutide uses C16; semaglutide uses a C18 diacid attached through a longer γGlu-2xOEG linker, and also substitutes Aib at position 8 to block DPP-4 directly. Stronger albumin binding plus enzymatic protection moves the half-life from hours to about a week. The two molecules are the same strategy executed at different intensities.

Where it sits now

Liraglutide has been overtaken on effect size and convenience by weekly analogues, and by the dual and triple agonists beyond them. It retains historical significance as the first GLP-1 analogue derived from the human sequence rather than from venom, and as the compound that established albumin binding as the standard route to half-life extension in this class.

The pattern it established

Look at semaglutide, tirzepatide and retatrutide and the same feature appears in each: a fatty diacid chain for albumin binding, with length and linker tuned to the dosing interval required. Liraglutide is where that pattern starts. Understanding it explains the structural family resemblance across compounds targeting quite different receptors.

Quick reference

ExenatideLiraglutideSemaglutide
OriginGila monster venomHuman GLP-1 analogueHuman GLP-1 analogue
Homology to GLP-1~53%~97%~94%
DPP-4 resistanceNatural (Gly2)PartialAib8 substitution
Lipid chainNoneC16 palmiticC18 diacid
DosingTwice daily / weeklyOnce dailyOnce weekly

Frequently asked questions

Why is liraglutide daily rather than weekly?

Its C16 chain binds albumin less strongly than semaglutide's C18 diacid, and it lacks the Aib substitution that blocks DPP-4 directly. Half-life is around 13 hours rather than about a week.

Is liraglutide closer to human GLP-1 than exenatide?

Much closer, about 97% homology against exenatide's 53%. Exenatide is a different peptide that happens to fit the same receptor.

Is liraglutide still relevant?

It has been overtaken clinically, but it established albumin binding as the standard half-life extension strategy that every later compound uses.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.